Immune System News and Research

RSS

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

GeoVax Labs, Inc., announced today that early results from part A of an ongoing phase 2a clinical trial indicate an excellent safety profile and highly reproducible immunogenicity.

10 Dec 2010

Researchers target MIC-1 protein to halt growth of melanoma tumors

Halting the growth of melanoma tumors by targeting the MIC-1 protein that promotes blood vessel development in tumors may lead to better treatment of this invasive and deadly cancer, according to Penn State College of Medicine researchers in The Foreman Foundation Research Laboratory.

10 Dec 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Memgen, LLC announced the presentation of clinical and preclinical results for its lead product, ISF35, during the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The research and clinical development of ISF35 announced today was led by Januario Castro, MD, and Thomas Kipps, MD, PhD, both at the University of California, San Diego.

10 Dec 2010

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have discovered some of the key molecular events in the immune system that contribute to inflammatory bowel disease. The results, which help researchers move one step further in their efforts to develop new drugs to treat inflammatory and immune-mediated diseases, are reported in the November 2010 edition of the journal Mucosal Immunology from the Nature Publishing Group.

10 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

Geisinger Medical Center performs first transcervical thymectomy

The Department of Thoracic Surgery at Geisinger Medical Center (GMC) recently performed its first transcervical thymectomy, joining other major academic medical centers nationwide that perform the minimally invasive surgical procedure.

9 Dec 2010

VIRxSYS presents study results of VRX1116 at HIV DART 2010

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies, today presented results from a study of VRX1116 at HIV DART 2010 in Los Cabos, Mexico, showing that vaccinated monkeys challenged with highly pathogenic simian immunodeficiency virus achieve sustained viral load reduction, preservation of the immune system and increased survival compared to controls.

9 Dec 2010

Rapid TB test endorsed by WHO

The World Health Organization (WHO) said that a new test that can detect tuberculosis (TB), including drug-resistant forms, in less than two hours could revolutionize treatment of the disease. Tuberculosis is still a major killer worldwide killing 4,700 people every day last year. The annual death toll of 1.7 million includes 380,000 people who are at particular risk because they have HIV, the virus that depresses the immune system and causes Aids.

8 Dec 2010

Lung transplant saves economist from near-lethal bout of swine flu

According to the critical care experts at The Johns Hopkins Hospital who treated him, Allen Bagents, 24, of Arlington, Va., is the least likely person anyone ever expects to get sick, let alone suffer a six-week, potentially fatal bout with the swine flu, better known as H1N1 influenza.

8 Dec 2010

Overeating and drinking at holiday parties could affect those unaware of type 2 diabetes

For most people, overeating and drinking at holiday parties will just result in weight gain. However, for millions of others who do not know they have type 2 diabetes, it could mean something much more serious.

8 Dec 2010

SEEK reports Phase I safety trail for investigational flu vaccine

SEEK, a leading UK privately-owned drug-discovery group, today presented data on the successful conclusion of a Phase I safety and tolerability study for its investigational Universal Influenza Vaccine, FLU-v, at the World Influenza Congress in Amsterdam (7-9 December).

8 Dec 2010

Loss of healthy bacteria may contribute to increasing rates of depression, say researchers

In an effort to pinpoint potential triggers leading to inflammatory responses that eventually contribute to depression, researchers are taking a close look at the immune system of people living in today's cleaner modern society.

8 Dec 2010

Nanoparticles could combat Listeria

A Purdue University research team developed a nanoparticle that can hold and release an antimicrobial agent as needed for extending the shelf life of foods susceptible to Listeria monocytogenes.

8 Dec 2010

Early group daycare exposure protects kids from infections later: Study

A new study reassures parents that although young kids might get sick more often when they first start group childcare, these same kids get fewer infections later in their childhood. About one in three U.S. kids receives organized childcare before reaching kindergarten age, whether at a daycare center or a school.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP (R-CHOP) chemotherapy, improved remission status of adult patients with diffuse large B-cell lymphoma (DLBCL), a form of aggressive lymphoma.

7 Dec 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the presentation of the CRS-207 Phase 1 study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. Dr. Le reported that CRS-207 intravenous administration was well tolerated in subjects with advanced, treatment-refractory cancers. Dr. Le also reported evidence of immune activation and that 6 out of 17 end-stage cancer patients lived 15 months or longer.

7 Dec 2010

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

The Norwegian biopharmaceutical company Lytix Biopharma and the Korean biotechnology company KAEL-GemVax announced today the successful first treatment in the study of a combination of LTX-315 and GV1001 as anti-cancer vaccine therapy.

7 Dec 2010

Scientists identify protein that disseminates biofilm-associated infection

What:Scientists from the National Institutes of Health have discovered how catheter-related bacterial infection develops and disseminates to become a potentially life-threatening condition. The study, which included research on Staphylococcus epidermidis in mice implanted with catheters, could have important implications for understanding many types of bacterial biofilm infections, including those caused by methicillin-resistant S. aureus (MRSA).

7 Dec 2010

Immune System News and Research

GeoVax's phase 2a trial results indicate excellent safety profile for HIV vaccine

Researchers target MIC-1 protein to halt growth of melanoma tumors

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Some key molecular events in immune system contribute to inflammatory bowel disease: Scientists

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Geisinger Medical Center performs first transcervical thymectomy

VIRxSYS presents study results of VRX1116 at HIV DART 2010

Rapid TB test endorsed by WHO

Lung transplant saves economist from near-lethal bout of swine flu

Overeating and drinking at holiday parties could affect those unaware of type 2 diabetes

SEEK reports Phase I safety trail for investigational flu vaccine

Loss of healthy bacteria may contribute to increasing rates of depression, say researchers

Nanoparticles could combat Listeria

Early group daycare exposure protects kids from infections later: Study

John Theurer Cancer Center presents research findings at ASH meeting

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Phase 1 study results of Aduro BioTech's CRS-207 presented at AACR Conference on Tumor Immunology

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

Scientists identify protein that disseminates biofilm-associated infection

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News